Brought to you by 
Gilead acquires remaining Corus shares for $365mm
22 Aug 2006
Executive Summary
Following a $25mm equity investment three months ago, anti-infectives company Gilead Sciences exercised its option to buy the rest of Corus Pharma's (respiratory and infectious diseases) shares for $365mm. Corus becomes a wholly owned subsidiary when the deal closes, expected in the third quarter of this year.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gilead acquires remaining Corus shares for $365mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice